The introduction of trastuzumab, a humanized monoclonal antibody directed against the extracellular subdomain IV of the HER2 protein, has paved the way for the development of HER2-targeted therapies in HER2-overexpressing (hereafter referred to as HER2+) cancers, particularly breast cancer [3]. Here, ERBB2 is linked to breast cancer.